Cystemustine

Drug Profile

Cystemustine

Alternative Names: CMSO2EN2

Latest Information Update: 31 Oct 2002

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Antineoplastics; Nitrosourea compounds; Small molecules
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Colorectal cancer; Glioma; Head and neck cancer; Malignant melanoma; Renal cancer; Sarcoma

Most Recent Events

  • 23 Mar 2000 A phase II study in melanoma has been added to the therapeutic trials and adverse events sections
  • 03 Aug 1999 Preclinical studies have been added to the pharmacodynamics section
  • 19 May 1997 Phase-II clinical trials for Glioma in France (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top